Sana Biotechnology Inc vs US Foods Holding Corp. Common Stock — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $812.76M), while US Foods Holding Corp. Common Stock trades at $97.36 (market cap $20.78B). The key difference: US Foods Holding Corp. Common Stock is far larger — about 25.6× Sana Biotechnology Inc's market cap, and US Foods Holding Corp. Common Stock is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and US Foods Holding Corp. Common Stock for 0 Days on average.
| SANA | USFD | |
|---|---|---|
Market Cap | $812.76M | $20.78B |
Volume | 4,314,200 | 1,109,124 |
Sector | Health | Industrials |
52-Week High | $5.92 | $110.94 |
52-Week Low | $2.68 | $70.05 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $726.01M | $26.13B |
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.72, down 1.09% today, showing bearish technical signals with negative moving averages but oversold RSI readings. The company reported no revenue in 2025 with substantial losses (-$244.17M net income) and negative cash flow (-$55.33M), though analyst sentiment remains positive with 82% buy ratings. Recent investor conference presentations highlight ongoing clinical development activities.
While analyst consensus is bullish with a $9.50 price target (Defense World, July 30, 2026), SANA faces significant fundamental challenges including negative profitability metrics and cash burn. Investment appeal hinges on clinical pipeline success, with risks including execution challenges and the pre-revenue biotech business model requiring continued financing.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →US Foods distributes food and related products to foodservice operators. Its customers include restaurants, healthcare providers, hospitality businesses, government institutions, and educational organizations.
Read more on USFD →